20 articles
Researchers shift from systemic B-cell targeting to localized immune control, potentially improving transplant success rates.
Researchers explore targeted immune strategies to improve pancreatic islet transplant success rates for diabetes treatment.
New research reveals how blood vessel maturity around transplanted insulin-producing cells determines long-term survival.
A large real-world study finds post-transplant diabetes requiring insulin marks a high-risk metabolic phenotype with far worse graft and patient outcomes.
A novel endoluminal device implanted in the gut improved insulin sensitivity and weight control beyond what semaglutide achieved in a pig model.
Scientists identify how different immune cells use specific nutrient transporters, revealing new targets for autoimmune diseases.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
A novel mathematical model using deuterium MRI shows gastric bypass redirects nearly all ingested glucose through the liver, with more peripheral disposal.
A new ESRRA-ATG5 axis links mitochondrial recycling to arginine metabolism, and a plant polyphenol activates it to protect diabetic kidneys.
A novel conjugate merges GLP-1/GIP incretin signaling with pan-PPAR activation in one molecule, potentially revolutionizing metabolic therapy.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
The triple agonist retatrutide drives deep metabolic shifts beyond weight loss, improving key biomarkers of cardiovascular and insulin health.
A new review maps how tirzepatide's dual GIP/GLP-1 action reshapes metabolism across the pancreas, liver, gut, heart, kidneys, and brain.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
Research reveals how the steroid hormone pregnenolone allows cancer cells to evade immune detection and reduces immunotherapy effectiveness.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
New research shows melatonin supplementation during IVF can prevent obesity and glucose problems in offspring by restoring liver function.
